["{\n\"step_by_step_thinking\": \"The relevant documents mention L-Dopa-carbidopa combination therapy for Parkinson's disease, which is an example of a decarboxylase inhibitor. The ideal agent has not yet been found. However, we present the results of the treatment of 50 patients on combined therapy using L-Dopa combined with Carbidopa. On the other hand, there are studies about anticholinergic agents such as ipratropium bromide and pirenzepine. None of these documents explicitly mention the given options (Glycopyrrolate, Atropine, Hyoscine butylbromide, and Hyoscine hydrobromide) as not crossing the blood brain barrier. But one of them is used in combination therapy with L-Dopa to make it more readily and rapidly available for brain metabolism.\",\n\"answer_choice\": \"D\"\n}"]